Attovia Therapeutics logo

Attovia Therapeutics

ATTO | NASDAQ
Chart Builder DCF Calculator
$14.72
-$0.41 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET
-2.71%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
29
+4.0 pts
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #832/1021 (Top 81%)

Key Statistics

Market Data

Market Cap $673.12M
1D Range
14.26 15.22
52W Range
13.73 25.55

Valuation (TTM)

PE -8.18
PB 1.69
EV/EBITDA -3.32

Valuation (NTM)

Forward PE N/A
Forward PEG 0.20
Price Target $45.00
Loading financial charts...

Profile

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-3...

Sector Healthcare
Industry Biotechnology
Employees 44
IPO Date Aug 5, 2026
Fiscal Year n/a

Latest News

No news articles available yet.

Earnings

Next Earnings
Dec 2, 2026
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$45.00
Upside
+205.71%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.